-Jogja Nov. 25, 2021- As an emerging biotechnology company in Indonesia, Tristem commits to the innovative development and manufacture of high-quality and safe stem cells therapy and its derivative and commercialization. Stem cell therapy is an accelerating regenerative medicine technology. The research in stem cell and derivative therapies are increasing each year. Stem cell therapy has been developed for clinical use for more than ten years in Indonesia; however, no stem cell therapy in Indonesia is hitherto approved and registered for clinical indication due to a limited number of clinical trials. In contrast, several stem cell therapy in other countries has been approved for a particular disease. These stem cells product could soon penetrate the Indonesian market and increase our dependency on imports. Thus, stem cell research, development, and commercialization acceleration are urgently needed. Tristem collaborates with UGM (Universitas Gajah Mada), a leading research University in Indonesia, to accelerate the development and research of stem cell therapy for clinical use. This partnership will provide synergy between academia and industry to advance research and implementation of stem cell technology in Indonesia.